Recently, Zhejiang University School of Management and Shenzhen Press Group Shenxin Communication Think Tank jointly released the "2021 China Listed Companies Innovation Index Report." The report selected 2384 Chinese A-share listed companies as the evaluation objects, constructed an evaluation model based on two dimensions of innovation strength and innovation efficiency, and launched three rankings: "2020 China Listed Companies Innovation Index Top 500," "2020 China Listed Companies Innovation Strength Top 200," and "2020 China Listed Companies Innovation Efficiency Top 200."
Healthyuan's innovative R&D strength has been repeatedly recognized by the industry. With a high innovation index score of 52.56, it successfully entered the "2020 China Listed Companies Innovation Index Top 500," ranking 266th! It also ranked 112th in the "2020 China Listed Companies Innovation Strength Top 200" with its excellent innovation capabilities!
In addition, LiZhu Pharmaceutical, a subsidiary of the group, also made the "2020 China Listed Companies Innovation Index Top 500," "2020 China Listed Companies Innovation Strength Top 200," and "2020 China Listed Companies Innovation Efficiency Top 200" rankings with its solid innovation and R&D capabilities, ranking 186th, 145th, and 196th respectively!
The report selected Chinese A-share listed companies as the evaluation objects, including main board, small and medium-sized enterprise board, and growth enterprise board. From two dimensions: innovation strength and innovation efficiency, based on seven indicators: R&D investment scale, R&D personnel scale, patent scale data, average sales profit margin, R&D intensity index, technical efficiency, and business model novelty, an evaluation model was constructed based on the assessment weights.
Innovation is both a leverage for Chinese domestic manufacturing enterprises to seek growth opportunities and an important cornerstone for China to build strength in global economic and industrial competition. The report covers five major categories and 35 secondary sub-sectors, including manufacturing, information transmission, software and information technology services, scientific research and technology services, and comprehensive industries. It has received widespread attention and recognition from society, and its influence covers the Yangtze River Delta, the Pearl River Delta, and Hong Kong and Macao regions, radiating across the country. Among them, Shenzhen has 39 companies on the Innovation Top 500 list, accounting for about half of the number of companies in Guangdong (81).
For the capital market, innovation capability is one of the barometers for enterprise value investment. After years of operation and development, Healthyuan has become an innovative R&D-oriented comprehensive pharmaceutical group company integrating pharmaceutical R&D, production, sales, and services. It has a diversified R&D team, focusing on building innovative high-barrier technology platforms such as monoclonal antibodies, inhalation preparations, long-acting sustained-release microspheres, and nano-lipid microemulsions. It pays particular attention to the R&D and updates in the field of inhalation preparations, and has successively launched milestone domestic inhalation preparation generic drugs such as "Shutanlin®," "Lishutong®," and "Wushu®," and successfully entered the national centralized procurement, achieving the development goal of replacing imports with domestic products.
Among the high-quality stocks in the pharmaceutical manufacturing sector, Healthyuan and Lizhu Group have always adhered to R&D innovation, maintaining excellent business performance by continuously strengthening project process management and balancing R&D quality and timeliness. Furthermore, a complete industrial chain layout, industry-leading innovation capabilities, sound financial condition, and lasting brand reputation and influence are key factors for institutions to remain optimistic about Healthyuan's future development.
